Clinical trials: Aortic Stenosis and Lipoprotein(a) Levels

Aortic Stenosis and Lipoprotein(a) Levels

Early Aortic Valve Lipoprotein(a) Lowering Trial

• Withdrawn
• Age: 50 to 85 years
• Early Phase 1

Aortic valve disease is the most common form of heart valve disease and is a major burden to society. Aortic valve disease is also expected to become more prevalent with the aging of the Canadian population.

Trial name

EAVaLL (NCT02109614)

Testing

Extended release Niacin

Where

3 sites in Canada

Sponsor

George Thanassoulis